人尿激肽原酶联合血小板抑制剂治疗脑梗死患者的疗效观察

目的人尿激肽原酶(尤瑞克林)联合血小板抑制剂治疗脑梗死患者的疗效观察。方法 88例脑梗死患者随机分为治疗组和对照组,每组44例。在对症治疗的基础上,对照组患者给予拜阿司匹林200～300mg/d,治疗组患者在对照组基础上加用尤瑞克林0.15 PNAU/d静脉滴注。两组疗程均为7天。用美国国立卫生研究院脑卒中量表(NIHSS)评估患者神经功能缺损,并观察凝血功能、血压变化。结果两组患者治疗前后凝血功能变化,差异无统计学意义(P>0.05)。与治疗前比较,两组患者治疗后NIHSS评分明显下降,差异有统计学意义(P<0.05),且治疗组较对照组NIHSS评分下降更明显(P<0.05),治疗组高血压患者在应用尤瑞克林治疗期间血压无明显波动(P>0.05)。结论尤瑞克林联合血小板抑制剂能有效治疗脑梗死.且安全性良好。

The efficacy of human urinary kallikrein combined with antiplatelet agents in treatment of patients with cerebral infarction

Objective To evaluate the efficacy of human urinary kallikrein combined with antiplatelet agents in treatment of patients with cerebral infarction. Methods Eighty-eight patients with cerebral infarction were randomly assigned to receiving 200-300 mg of aspirin daily or aspirin combined with human urinary kallikrein (0.15 PNAU/d) for 7 days on the basis of basic therapy. The primary efficacy in coagulation system, neurological deficits scale(NIHSS) score and blood pressure was evaluated. Results The study showed that human urinary kallikrein combined with antiplatelet agents had no effects on coagulation system and blood pressure, but could significantly reduce neurological deficits. Conclusions Human urinary kallikrein combined with antiplatelet agents can treat cerebral infarction effectively and safely.